28 Chagnac et al.29 demonstrated that renal hyperperfusion and hyperfiltration in severe obesity and hyperfiltration injuries can lead to the final pathway of glomerulosclerosis MK0683 price especially when the size of functioning nephron mass is substantially reduced. As a result, obesity might have more adverse effects in renal transplant recipients. A major limitation in our study is the relatively small sample size. Moreover, the underweight patients (BMI <18.5) in our study were not analyzed separately because of the limited number of patients. More patients should be recruited in order to see if Asian renal transplant recipients

with low BMI values have a higher mortality when compared with recipients with normal BMI values. Furthermore, lack of data for those with primary non-functioning kidneys was another limitation in this study because obese patients tend to experience more surgical problems which may result in early technically-caused graft loss. Finally, our obese patients were older and had a higher incidence of DM, so survival analysis could still

be biased because both were independent predictors of graft outcome. However, with the use BVD-523 ic50 of a multivariate model of factors associated with graft failure over time, we demonstrated that obesity was associated with decreased long-term graft survival independent of confounding factors such as DM and age. In conclusion, our study demonstrated that obesity was significantly associated with poor renal graft function and decreased patient and graft survival in Asian renal transplant recipients. In addition, overweight was associated with a lower estimated GFR. However, no significant difference in patient and graft survival could be demonstrated between the overweight group and the normal group. Further studies are required to

validate the optimal target BMI in our renal transplant recipients. Moreover, we also showed that obesity, older age, Telomerase presence of pre-transplant DM and acute rejection were all independent risk factors for graft failure in our patients. “
“Aim:  Diabetic patients are at higher risk of failure to recover after acute kidney injury, however, the mechanism and therapeutic strategies remain unclear. Erythropoietin is cytoprotective in a variety of non-haematopoietic cells. The aim of the present study was to clarify the mechanism of diabetes-related acceleration of renal damage after ischaemia–reperfusion injury and to examine the therapeutic potential of asialoerythropoietin, a non-haematopoietic erythropoietin derivative, against ischaemia–reperfusion-induced acute kidney injury in diabetic mice. Methods:  C57BL/6J mice with and without streptozotocin-induced diabetes were subjected to 30 min unilateral renal ischaemia–reperfusion injury at 1 week after induction of diabetes.